Our research team at the University of Sydney has established groundbreaking methods for understanding multiple sclerosis progression through advanced imaging and computational analysis. Our work has revealed crucial insights into how chronic lesions expand over time and contribute to disability accumulation, fundamentally changing our understanding of MS progression. Through innovative techniques like our Lesion Estimation and Analysis Pipeline (LEAP), we’ve demonstrated that chronic lesion expansion follows distinct patterns and plays a pivotal role in disease advancement.

We are now poised to translate these discoveries into clinical practice through our landmark COMPASS-MS study (Comparing Outcomes of Multiple Pharmacotherapies on Active Smouldering Sites in MS). This world-first international initiative will evaluate how current MS treatments affect smouldering inflammation—a critical driver of disease progression that our research has helped identify and measure. By leveraging our validated quantitative biomarkers across multiple international centres, COMPASS-MS promises to revolutionise our understanding of treatment efficacy and guide more personalised therapeutic approaches.

To advance this transformative research agenda, we actively seek funding partnerships and support. Your contribution would directly enable:

• Implementation of the COMPASS-MS retrospective cohort study across international centres
• Continued development of our innovative lesion analysis methodologies
• Enhancement of our computational capabilities for processing large-scale clinical datasets
• Expansion of our longitudinal studies tracking lesion evolution
• Translation of findings into practical clinical guidelines for optimising MS treatment

We welcome enquiries from organisations and individuals interested in supporting this groundbreaking work through funding, collaboration, or other partnerships. Your support will help accelerate the development of more effective treatments for MS and contribute to better outcomes for patients worldwide.